Clinical trial
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed…
NCT00087620 · Hoffmann-La Roche, Industry · Terminated
Key facts
| NCT number | NCT00087620 |
|---|---|
| Title | A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | XELODA [capecitabine] |
| Start date | Sep 1, 2004 |
| Primary completion | Oct 1, 2004 |
| Completion | Oct 1, 2004 |
| First posted | Jul 14, 2004 |
| Last update posted | Feb 3, 2017 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: